Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

All

ATC	Name	B/G ↑	Ingredients	Dosage	Form	Price
N05AX13	INVEGA	B	Paliperidone - 9mg	9mg	Tablet, extended release	5,825,557 L.L
N05AX13	INVEGA	B	Paliperidone - 3mg	3mg	Tablet, extended release	5,386,121 L.L
N05AX13	INVEGA	B	Paliperidone - 6mg	6mg	Tablet, extended release	5,825,557 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 100mg	100mg	Injectable suspension, prolonged release	19,068,505 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 75mg	75mg	Injectable suspension, prolonged release	15,240,102 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 50mg	50mg	Injectable suspension, prolonged release	9,661,754 L.L
N05AX13	INVEGA SUSTENNA	B	Paliperidone palmitate - 150mg	150mg	Injectable suspension, prolonged release	27,480,995 L.L
A07DA03	IMODIUM	B	Loperamide HCl - 2mg	2mg	Capsule	138,416 L.L
A07DA03	IMODIUM INSTANTS	B	Loperamide HCl - 2mg	2mg	Tablet, orodispersible	451,531 L.L
L01EA05	ICLUSIG	B	Ponatinib - 15mg	15mg	Tablet, film coated	103,555,839 L.L
L01EA05	ICLUSIG	B	Ponatinib - 45mg	45mg	Tablet, film coated	207,092,651 L.L
L01EB01	IRESSA	B	Gefitinib - 250mg	250mg	Tablet, fim coated	135,027,509 L.L
A07FA51	INFLORAN	B	Bifidobacterium infantis - 1milliard, Lactobacillus acidophilus - 1milliard		Capsule	647,732 L.L
L01EF01	IBRANCE	B	Palbociclib - 75mg	75mg	Capsule	172,164,216 L.L
L01EF01	IBRANCE	B	Palbociclib - 75mg	75mg	Tablet, film coated	172,164,216 L.L
L01EF01	IBRANCE	B	Palbociclib - 100mg	100mg	Capsule	172,164,216 L.L
L01EF01	IBRANCE	B	Palbociclib - 100mg	100mg	Tablet, film coated	172,164,216 L.L
J07BB01	INFLUVAC TETRA	B	Influenza virus surface antigens inactivated (haemagglutinin and neuraminidase) - 15mcg/4strains/0.5ml		Injectable suspension	970,254 L.L
L01EF01	IBRANCE	B	Palbociclib - 125mg	125mg	Capsule	172,164,216 L.L
J07BB02	INFLUVAC	B	Grippal virus surface antigen 3strains - 15mcgx3strains/0.5ml		Injectable suspension	573,821 L.L
L01EF01	IBRANCE	B	Palbociclib - 125mg	125mg	Tablet, film coated	172,164,216 L.L
L01EL01	IMBRUVICA	B	Ibrutinib - 420mg	420mg	Tablet, film coated	L.L
L01EK01	INLYTA	B	Axitinib - 5mg	5mg	Tablet, film coated	184,486,511 L.L
L01EK01	INLYTA	B	Axitinib - 1mg	1mg	Tablet, film coated	57,595,789 L.L
L01EL01	IMBRUVICA	B	Ibrutinib - 140mg	140mg	Tablet, film coated	194,761,420 L.L
J07CA06	INFANRIX IPV + HIB	B	Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen(Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg, Tetanus toxoid (Prefilled syringe) - ?40IU, Diphtheria toxoid (Prefilled syringe) - ?30IU, H. Influenza type b polysaccharide(Vial) - 10mcg		Injectable dry powder+suspension	3,014,239 L.L
L01EL01	IMBRUVICA	B	Ibrutinib - 420mg	420mg	Tablet, film coated	584,283,050 L.L
L04AX06	IMNOVID	B	Pomalidomide - 4mg	4mg	Capsule, hard	L.L
J07CA09	INFANRIX HEXA	B	Diphteria toxoid purified (Prefilled syringe) - ?30IU/0.5ml, Tetanus toxoid purified (prefilled syringe) - ?40IU/0.5ml, Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg/0.5ml, Poliomyelitis virus type 1 antigen (prefilled syringe) - 40D.U./0.5ml, Poliomyelitis virus type 2 antigen(prefilled syringe) - 8D.U./0.5ml, Poliomyelitis virus type 3 antigen (prefilled syringe) - 32D.U./0.5ml, HBs Antigen (prefilled syringe) - 10mcg/0.5ml, H. Influenza type b polysaccharide (Vial) - 10mcg/0.5ml		Injectable suspension	4,230,416 L.L
R07AA	INFASURF	B	Calfactant - 210mg/6ml	35mg/ml	Injectable suspension	40,596,749 L.L